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Some people believe that the impact of population ageing on future health care ex-
penditures will be quite moderate due to the high costs of dying. If not age per se but 
proximity to death determines the bulk of expenditures, a shift in the mortality risk to 
higher ages will not affect lifetime health care expenditures as death occurs only 
once in every life. We attempt to take this effect into account when we calculate the 
demographic impact on health care expenditures in Germany. From a Swiss data set 
we derive age-expenditure profiles for both genders, separately for persons in their 
last four years of life and for survivors, which we apply to the projections of the age 
structure and mortality rates for the German population between 2002 and 2050 as 
published by the Statistische Bundesamt.  
We calculate that at constant prices per-capita health expenditures of Social Health 
Insurance would rise from € 2,596 in 2002 to between € 2,959 and € 3,102 in 2050 
when only the age structure of the population changes and everything else remains 
constant at the present level, and to € 5,485 with a technology-driven exogenous 
cost increase of one per cent per annum. A “naïve” projection based only on the age 
distribution of health care expenditures, but not distinguishing between survivors and 
decedents, yields values of € 3,217 and € 5,688 for 2050, respectively. Thus, the er-
ror of excluding the “costs of dying” effect is small compared with the error of under-
estimating the financial consequences of expanding medical technology.  
  1 1 Introduction 
Financing the modern welfare state in the future is commonly believed to be one of 
the most urging problems in today’s politics. Presently, German workers pay 42 per 
cent of their payroll for social insurance, a high tax wedge that is detrimental for em-
ployment. Therefore, politicians are desperately searching for ways to prevent or at 
least alleviate a further dramatic increase in the costs of social insurance over the 
next 30 to 40 years, e.g. by introducing a „sustainability factor“ in the calculation of 
retirement benefits.  
A big uncertainty is connected with the development of the expenditures of 
Social Health Insurance (henceforth: SHI) because its benefits are predominately in 
kind rather than cash, and the nature of the respective product „health care“ will 
change through technical progress in medicine as the structure of demand will 
change through a rising life expectancy. There have been numerous attempts to 
forecast the development of the average payroll contribution rate of German sickness 
funds. The spread of rates is rather wide. In his survey of forecasts, which have been 
published since 1995, Postler (2003, p. 23) reports on contribution rates for the year 
2050 of between 16.5 and 39.5 per cent, where the lower values refer to simulations 
of the effect of demographic change alone, ignoring any expenditure growth due to 
progress in medical technology.
1  
The uncertainty expressed in this wide spread, critical for health and social pol-
icy plans, has led to a fierce controversy on the need of a fundamental reform of the 
system of health care financing in the long run. Even the rather timid attempts to in-
troduce more self-responsibility of patients, e.g. through a physician service fee of 10 
Euro per quarter, are attacked by trade unions and social democratic leftists to be the 
beginning of the dismantling of the welfare state. All the more, members of these cir-
cles openly deny that it may become necessary within the next decades to limit the 
set of basic benefits in SHI and in turn to widen the scope of supplementary private 
insurance. Politicians, for the same reason, are reluctant to introduce further legisla-
tion that would restrict the benefit package of SHI in the long run as such programs, 
interpreted as welfare state retrenchment, may risk the loss of many votes.  
                                                           
1 The current average contribution rate in the German SHI is 14.2 per cent. 
  2 This reluctance runs the danger that inevitable reforms will later hit the citizens 
unexpectedly and might place a much heavier burden on them than a timely long-run 
policy. In particular, the build-up of private, capital-funded supplementary insurance 
requires a time lead of several decades.
2 For these reasons, it is important to reduce 
those controversies, which are derived from uncertainty of the future development. 
A closer inspection differentiates three factors affecting future contribution 
rates, 
1. the impact of population ageing on the incomes, on which sickness fund contribu-
tions are levied: the latter shrinks when the share of workers in total population 
falls; 
2. the impact of ageing, in particular of the growth in life expectancy on per-capita 
expenditures; 
3. the impact of medical progress on per-capita expenditures.  
The first effect would be eliminated by a transition from income-related contri-
butions to per-capita premiums since pensioners would then have to pay the same 
rates as workers. The sign of the third effect is hardly controversial since there is by 
now a wide-spread agreement that medical progress predominantly consists of new 
products and procedures with both higher quality and costs. Only the size of this ef-
fect is still somewhat unclear. Breyer and Ulrich (2000) estimated it from the coeffi-
cient of time in a regression of per-capita expenditures on age structure and income, 
finding a growth rate of one per cent per annum. 
Hence, it is the second effect that is at the center of the controversy on the fu-
ture development of health care expenditures. There are at least three hypotheses 
on the impact of an increase in life expectancy on health care costs with constant 
medical technology: 
a) The status-quo hypothesis assumes that age-specific per-capita expenditures de-
pend only on the state of medical technology and remain stable when the latter is 
controlled for. The impact of life expectancy can be calculated by applying present 
age-expenditure profiles on the future age distribution of the population (see, e.g., 
PROGNOS 1998). 
                                                           
2 See, e.g., Breyer (2000). 
  3 b) The medicalization hypothesis (Krämer 1993, 1996) is based on the observed mul-
timorbidity of many elderly patients and states that new possibilities of treating a 
specific type of illness (e.g. heart disease) prolong the patient’s life without per-
fectly restoring his/her health so that shortly after another disease sets in (e.g. 
cancer), which requires additional treatment. According to this hypothesis, the 
main effect of technical progress in medicine is to prolong the life of those patients 
who are so sick that they would otherwise die, implying that average health status 
of the population deteriorates over time. This explains  Krämer’s dictum (1993, p. 
31) that “we spend the largest part of the additional years in the sickbed“. 
c) The compression hypothesis is based on the conjecture that the observed differ-
ence in the health care expenditures between young and old persons in cross-
sectional data are not primarily due to calendar age, but are caused by the differ-
ences of time to death (e.g. Fuchs 1984): in higher age groups, a larger share of 
persons is in their last years of life, in which – in a futile attempt to prevent death – 
a high amount of money is spent for medical treatment. In such a situation, an in-
crease in life expectancy – caused by medical progress or simply by a healthier 
life style – lowers age-specific death rates and thus fewer persons are in their last 
years of life in each age group. In other words, the years with high expenditures 
towards the end of life are compressed and constitute a smaller share of the total 
lifespan. 
While the medicalization hypothesis claims that a naïve simulation of future health 
expenditures on the basis of present age-expenditure profiles underestimates the 
true growth in health expenditures (even with constant medical technology), the weak 
compression hypothesis suggests the exact opposite. The strong compression hy-
pothesis, moreover, claims that an increase in life expectancy – through a drop in the 
total mortality rate – will even lower per-capita health care expenditures. 
There is hardly any empirical evidence in favor of the medicalization hypothe-
sis. On the contrary, Dinkel (1999), exploring data from the German microcensus, 
finds that younger cohorts (birth years 1919 and 1913) not only experienced more life 
years beyond age 60 than older ones (birth year 1907) but an even larger increase of 
healthy life years. On the other hand, the compression hypothesis stands on a firm 
empirical basis: the increase of treatment costs in the years before death has been 
convincingly documented in numerous studies with data from various countries (e.g. 
  4 Lubitz and Riley 1993, Zweifel et al. 1996, 1999, Stearns and Norton 2004, Sesha-
mani and Gray 2004a, 2004b).  
An additional effect, further strengthening the compression hypothesis, is the 
reluctance of physicians to treat very old terminally ill patients as aggressively as they 
treat younger patients with similar symptoms, a behavior commonly interpreted as 
„age-based rationing“. To the extent that this lets costs of dying decrease with age 
beyond a certain threshold, it accentuates the overestimation of future expenditures 
in status-quo predictions. The empirical evidence on the decline of the cost of dying 
at a very high age is unambiguous. Although Zweifel et al. (1996, 1999) found no 
significant age impact on health care expenditures among deceased persons in Swit-
zerland, they report a decline of the costs of dying among the over 65-years-old de-
cedents, a finding that was confirmed by Felder et al. (2000) and Schellhorn et al. 
(2000). Lubitz et al. (1995) showed that Medicare expenditures in the last two years 
of life for 70-years-old decedents were around 50 per cent higher than for persons 
who died at age 90. Similarly, Busse et al. (2000) found in a German sample that the 
number of hospital days in the last year of life peaked at the age group 55 to 64 and 
declined steadily with rising age of dying thereafter. 
Even if it is no longer questionable that the status-quo hypothesis overesti-
mates the impact of demographic ageing on per-capita health care expenditures it is 
still interesting to assess the extent of the error. A first, rather crude attempt by 
Breyer (1999), using hospital days of surviving and deceased patients, estimated that 
the true ageing-related increase in total expenditures will amount to only 40 per cent 
of the one calculated with a status-quo projection.  
Now, a new data set from a Swiss sickness fund allows a much more precise 
assessment of the error in a naïve forecast. This data set contains the annual health 
care expenditures of over 91,000 persons of whom approximately four per cent died 
within a time span of three and a half years. Using a regression analysis, we estimate 
age-expenditure profiles for men and women, each separated by survival status (sur-
vivors versus decedents). Applying these expenditure profiles to the age structure of 
the German population in the coming decades as predicted by the Statistische 
Bundesamt,
3 taking the estimated age-specific death rates into account allows an as-
                                                           
3 Statistisches Bundesamt (2003), 10. koordinierte Bevölkerungsvorausberechnung, Wies-
baden. 
  5 sessment of the purely ageing-related increase in health care expenditures. By con-
trasting this „sophisticated“ projection with a ”naïve“ status-quo prediction, it will be 
possible to assess the extent of the error more precisely than it was possible with 
previous data sets. 
In the following we shall compare three different scenarios. In the first sce-
nario, age-specific average health expenditures of the year 2002 will be directly ap-
plied to the age composition expected for future decades. In the second scenario, we 
distinguish explicitly between persons in their last four years of life and those who 
survive longer than that. In the third scenario, we take the compression hypothesis 
literally by adjusting the age-specific expenditures rightward by the difference in age-
specific remaining life expectancies. For example, if the remaining life expectancy of 
a 65-year old will increase by 4 years until 2050, we shall assume that a 65-year old 
in 2050 will only spend as much as a 61-year old today. 
To avoid possible misinterpretations of our study, we emphasize that we do 
not attempt to forecast future health care expenditures. Instead we try to calculate a 
contrafactual, namely what the expenditures in 2002 would have been if the demo-




The remainder of this paper is organized as follows. In Section 2 we describe 
the data and explain our methodology, in Section 3 we present the results, while Sec-
tion 4 concludes. 
2 Data and Methods 
A Swiss sickness fund made 1999 claims data of 91,327 persons available to us. Of 
these persons, four per cent died between January 1
st, 2000 and June 30
th, 2003, i.e. 
96 per cent survived the year 1999 by at least 42 months. The data set allowed us to 
estimate the impact of both age and time to death on health care expenditures for 
both survivors and decedents. To account for the fact that in any given year there are 
persons with zero expenditures, we performed a two-stage estimation of individual 
health care expenditures (Hi) with the following result: 
                                                           
4 We are not interested in the effect of demographic change on total health expenditures, 
which is at the center of the study by Schulz et al. (2004). 
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where A denotes age, M is a dummy variable for males, D is a dummy variable for 
decedents and TtD (“time to death”) measures the time span in months between De-
cember 31
st, 1999 and the date of death. For people still living at the end of the ob-
servation period we set TtD = 43..
5 Both the gender dummy and the dummy for de-
cedents are interacted with age to account for differences in the division of health ex-
penditures both between genders and by survival status. Expected health care ex-
penditures are calculated according to  ( ) = >⋅ > iii i H H Pr 0 0 HH  and are measured 
in Swiss Francs (SFr, 0.67 € at the current exchange rate). 
The estimates are limited to the age interval (30, 95). For persons below 30 
and above 95 years of age we set health care expenditures equal to the values at the 
boundaries of the interval. When we insert the values 6, 18, 30 and 42 for TtD in 
equations (1) and (2), we obtain estimates for health care expenditures in the last, 
last but one year of life and so forth. We get predicted annual expenditures of survi-
vors when we set D = 0 and TtD = 43. Figure 1 shows the per-capita health expendi-
tures as a function of age for the five groups defined above, separately for men and 
women. The rather flat U-shaped curves of all groups, in particular decedents, is due 
to the common estimation with a quadratic specification of the age variable
6. If we 
only look at health expenditures in the last year of life, we will get the well-known 
concave shape with decreasing expenditures beyond age 65. The sixth curve in Fig-
ure 1 represents predicted health expenditures as a function of age if the information 
on the survival status is ignored. It is derived from the following regression equations:  
() ( =− ⋅ + ⋅ − ⋅ +⋅ ⋅
2





HA M ) i i A M  (3) 
( ) >= − ⋅ + ⋅ + ⋅ − ⋅ ⋅ ii i i i i i HH A A M AM
2 0 11.106 382 4.015 978 14,94 . (4) 
                                                           
5 Alternatively, we used dummy variables for survivors and persons in their last year, last-but 
one year etc., which did not change the results. For the estimation, the metric approach is 
easier to use. 
  7 Figure 1: Predicted expenditures (in SFr) of women and men: persons in their last 
year (D_0), last year but one (D_1), last year but two- (D_2), last year but 
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The graph of this ”naïve“ estimate of health care expenditures is steeper 
above age 50 than the curves for the individual groups because of the effect of rising 
mortality with age. 
 
                                                                                                                                                                                     
6 For details of the regression’s specification see Zweifel et al. (2004).  
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The second data source is derived from the population forecasts of the Ger-
man Statistical Office for the time span until 2050. From the numbers of persons at 
the respective age in consecutive years (2002, 2010 - 2050), we can calculate the 
age-specific probabilities to die in the present, in the next year, in two and in three 
years time ( () () ( ) () , 1 , 2 , 3 A qA A gA A qA A +++ qA ). Hence, the probability to sur-
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Figure 2, comparing the four-year survival rates in the years 2002 and 2050 
reveals a rectangularization of the age-specific survival rates due to the increase in 
life expectancy. 
According to the compression hypothesis, the increase in life expectancy will 
lead to a flatter age-expenditure profile. We take this effect into account in a separate 
scenario in which we adjust the age of the surviving individuals downward by the in-
crease in life expectancy: 
() 2002 tt A , t A , A A LE LE =− − %  .    (5) 
The procedure can be illustrated for a 60-year old man whose remaining life expec-
tancy is predicted to increase until 2050 from 19.5. to 23.7 years. Following equation 
(5), the 60-year old man will be assigned the age “56” in the 2050 demographic struc-
  9 ture and thus will be imputed lower health expenditures than a 60-year old man in 
2002. 
3 Results 
We combined the two data sets described above, age-expenditure profiles for survi-
vors and decedents from Switzerland and the population forecast for Germany, to es-
timate the purely demographic impact on per-capita health expenditures until 2050 
when everything else, in particular technology and prices, is held constant. We dis-
tinguished the “q-model”, which takes into account the costs of dying and the expen-
ditures in the last four years of life, from the “n-model”, which contains a naïve projec-
tion of expenditures on the basis of the age and gender structure of the population 
alone.  
As a first step, we calibrated both models to Germany’s total health expendi-
tures in 2002, which amounted to € 186.41 billions. Calibration proceeded as follows: 
using  equations (1) and (2) or, alternatively, equations (3) and (4), together with the 
numbers of people in the age and sex classes of the German population in 2002, we 
calculated the German health care bill in Swiss franks. This figure, then, was ad-
justed to the actual bill in € and divided by the total German population in 2002. Thus, 
both models are able to produce per-capita health expenditures of € 236  per month, 
the figure quoted by the Statistische Bundesamt for that year. However, we chose a 
narrower definition of health expenditures, not comprising private health insurance 
payments and out-of-pocket expenses, thus arriving at monthly expenditures of € 
216.66 per capita.  
The projection of health care expenditures is derived from the forecast of age 
structure and mortality in the scenario V5 of the Statistische Bundesamt (medium 
values of immigration and life expectancy). We focus on per-capita expenditures 
which are the relevant measure from a financing point of view. In calculating the q-
model, we further distinguish q1 from q2, in which in addition to the separation be-
tween survivors and decedents, we adjust the age of survivors downward according 
to equation (5). 
  10  3.1 Only age structure changes 
Table 1 shows the development of per-capita expenditures until 2050, both for the n- 
and the q-model, assuming that everything but the age structure remains constant at 
year 2002 levels. According to the status-quo projection, expenditures would in-
crease by 23.9 per cent to € 3,217 per annum. If costs in the last years of life are 
taken into account, this growth is diminished to 19.5 per cent, a level of € 3,102 per 
annum in 2050. Taking the ratio of the two growth rates (.195 / .239 = .815), we see 
that, taking the naïve projection as our point of reference, the explicit distinction be-
tween survivors and decedents in the q1-model lowers the estimate of the expendi-
ture growth by 18.5 per cent or not quite one-fifth. In the q2-model, per-capita expen-
ditures rise only by 14 per cent to € 2,959. In this case, the error of the n-model 
amounts to about 40 per cent. 
Table 1:   Age-specific expenditures of 2002 and demographic change until 2050 
with and without costs of dying 
q-models  Error of the n-
model in per cent
n-model 
q1  q2 
year 
in €  2002=100  in €  2002=100 in €  2002=100
q1  q2 
2002 2,596  100.00  2,596  100.00  2,596  100.00  0  0 
2010 2,691  103.66  2,674  103.00  2,642 101.77  18.0  51.7 
2020 2,827  108.91  2,788  107.38  2,745 105.73  17.2  35.7 
2030 2,961  114.05  2,894  111.45  2,798 107.78  18.5  44.7 
2040 3,094  119.19  3,007  115.83  2,885 111.11  17.6  42.1 
2050 3,217  123.92  3,102  119.49  2,959 113.96  18.5  41.6 
 
In the two alternative population scenarios with low and high increase in life 
expectancy (V2 and V8, respectively), the growth in expenditures is corrected by 
13.9 and 22.9 per cent when costs of dying are taken into account. When in addition 
  11  the age-expenditure profile of survivors is adjusted for changes in life expectancy, we 
get error rates of 38.9 and 44.3 per cent, respectively. 
If we assume a low immigration rate and a medium rise in life expectancy 
(scenario V4), per capita expenditure growth equals 27.3 per cent  in the n-model  
22.7. per cent in the q1-model and 17 per cent in the q2-model, indicating that the 
immigration of on average younger persons will reduce the growth of Germany’s 
health care bill.   
If the purely demographic expenditure growth by 19.5 per cent in 48 years is 
transformed into a constant annual growth rate over the time span 2002 - 2050, this 
rate amounts to .37 per cent in the scenario V5. In the extreme scenarios of the 
change of life expectancy the annual demographic growth rate is .36 and .38 per 
cent. 
From these results, the following preliminary conclusions on the development 
of per-capita health expenditures with constant medical technology arise: 
1. The purely demographic growth of per-capita health expenditures is not really 
dramatic. 
2. The (strong) compression hypothesis, which claims that ageing as such will have 
no positive effect on per-capita health care expenditures since individual expendi-
tures are primarily a function of proximity to death, is not confirmed either. The ex-
plicit distinction between expenditures of survivors and those of decedents re-
duces the growth forecast only by one-fifth, and even assuming a rightward shift of 
the age-expenditure profile for survivors by the increase in life expectancy reduces 
it by only another fifth.  
 
3.2 Age structure and medical technology changes 
To forecast the total development of health care expenditures (at constant prices), it 
is necessary to account for the growth factor “technological change” in medicine, 
which has increased per-capita expenditures by one per cent per annum in the pe-
riod 1970 to 1995, holding income and age structure constant (Breyer and Ulrich 
  12  2000).
7 Factoring this growth rate into our models above, we will obtain the values in 
Table 2. The implicit assumption underlying this calculation is that there is no growth 
in real income because productivity gain is entirely made up of increased product 
quality.
8 Moreover, technical progress in medicine lets quality of medical care grow at 
a faster rate so that age-specific health expenditures rise by one per cent per year. 
Observe that under these assumptions per-capita expenditures would more than 
double in real terms until 2050, where the error of the n-model now amounts to only a 
small share (between six and fifteen per cent) of the total increase in expenditures. 
As an annual rate, per-capita expenditures will grow by 1.57 per cent between 2002 
and 2050. 
Table 2:   Age-specific  expenditures of 2002, demographic change until 2050 and 
medical progress (1 per cent growth per annum) 
q-models  Error of the n-
model in per cent
n-model 
q1 q 2 
year 
in €  2002=100 in €  2002=100 in €  2002=100
q1  q2 
2002 2,596  100.00 2,596  100.00 2,596 100.00  0  0 
2010 2,946  113.43 2,927  112.72 2,892 111.38  5.3 15.3 
2020 3,473  133.79 3,426  131.96 3,373 129.91  5.4 11.4 
2030 4,094  157.71 4,002  153.84 3,870 149.04  6.7 15.0 
2040 4,829  186.00 4,694  180.81 4,503 173.42  6.0 14.6 
2050 5,688  219.08 5,485  211.25 5,232 201.51  6.6 14.7 
                                                           
7 This figure is much smaller than the four per cent calculated by Fuchs (1999a, 1999b) for 
the excess of real growth of per-capita health care expenditures of the elderly over the 
growth rate of GDP. 
8 Thus our results are not directly comparable with forecasts of health expenditures in sce-
narios where real income rises over time, such as Breyer et al. (2004), p.149. 
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4 Concluding Remarks 
In the introduction we presented three alternative hypotheses referring to the impact 
of the increase in life expectancy on per-capita expenditures in SHI in Germany and 
countries with similar demographic challenges. Taking Swiss expenditure data as a 
basis, the (weak) compression hypothesis gets the strongest confirmation of these 
hypotheses: Explicitly accounting for costs in the last years of life leads to a down-
ward correction of the demographic impact on per-capita expenditures, as compared 
to a calculation on the basis of crude age-specific health expenditures. However, the 
error of the naïve calculation is much smaller than commonly asserted and amounts 
to slightly less than one-fifth of the predicted demographic effect on expenditures. 
Moreover, the impact of medical progress on health care expenditures is much larger 
than the impact of ageing so that taking this factor into account diminishes the rela-
tive importance of the error in the calculation of the demographic effect even further. 
Even when it is assumed that the whole age-expenditure profile shifts to the right by 
the increase in remaining life expectancy, a considerable part (60 per cent) of the es-
timated demographic increase in age-specific health expenditures until 2050 remains 
valid. 
For a number of reasons, the results presented here must be interpreted with 
caution. First, age-expenditure profiles of Switzerland do not have to be representa-
tive for Germany. In fact, the age-expenditure curve found in German data is some-
what flatter than the respective curve in the data used here.
9 Thus, we have probably 
overestimated the ”true“ demographic effect on expenditures in Germany so that our 
conclusion that the development of medical technology has the larger potential for 
expenditure growth than demographic change is corroborated. 
Finally, it must be emphasized that our analysis was restricted to the expendi-
ture side of financing SHI, thus ignoring the impact of population ageing on the in-
come basis, on which sickness fund contributions are levied. But given the tremen-
dous increase in expenditures over the next decades, the transition to per-capita 
                                                           
9 Publications of the Bundesversicherungsamt on the RSA (Risk Adjustment System) 2002; 
”Analytical“ Values (written communication). 
  14  premiums may be a necessary step to at least partially uncouple health care financ-
ing from demography.  
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